Description
Berteroin is a Erucin homolog that may exhibit antioxidative and anti-androgenic activities. Berteroin is an isothiocyanate (ITC) compound that decreases androgen receptor levels in prostate cancer cells. Berteroin also displays anti-inflammatory properties, decreasing LPS-induced release of pro-inflammatory cytokines in macrophages.